Stockscreener 앱 받기
52.73
2.42%
-1.41
전일 마감가:
$54.14
열려 있는:
$53.37
하루 거래량:
40,198
Relative Volume:
0.02
시가총액:
$8.28B
수익:
$1.17B
순이익/손실:
$150.71M
주가수익비율:
56.10
EPS:
0.94
순현금흐름:
$245.03M
1주 성능:
+2.51%
1개월 성능:
+4.57%
6개월 성능:
-29.31%
1년 성능:
-31.66%
1일 변동 폭
$52.29
$53.67
1주일 범위
$51.26
$55.52
52주 변동 폭
$46.01
$83.62
바이오-테크네 Stock (TECH) Company Profile
명칭
Bio Techne Corp
전화
(612) 379-8854
주소
614 MCKINLEY PL N E, MINNEAPOLIS, MN
TECH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TECH
Bio Techne Corp
|
52.84 | 8.08B | 1.17B | 150.71M | 245.03M | 0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.20 | 117.98B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
566.46 | 58.10B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
315.13 | 42.26B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.03 | 33.42B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.19 | 26.08B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오-테크네 Stock (TECH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-30 | 개시 | Wells Fargo | Overweight |
| 2025-04-09 | 다운그레이드 | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2025-03-18 | 개시 | Evercore ISI | Outperform |
| 2025-02-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-22 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-02-08 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-02 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-07 | 개시 | UBS | Buy |
| 2023-08-28 | 개시 | William Blair | Outperform |
| 2023-01-10 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-12-12 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-12-07 | 개시 | RBC Capital Mkts | Sector Perform |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-04-25 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2021-09-15 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-08 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2021-02-23 | 업그레이드 | Stifel | Hold → Buy |
| 2021-01-25 | 재확인 | The Benchmark Company | Buy |
| 2020-11-10 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | 개시 | Atlantic Equities | Overweight |
| 2020-07-15 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2020-05-27 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-14 | 개시 | The Benchmark Company | Buy |
| 2020-01-08 | 재개 | Stephens | Overweight |
| 2020-01-08 | 개시 | Wells Fargo | Equal Weight |
| 2020-01-07 | 개시 | Citigroup | Neutral |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-07-02 | 업그레이드 | Janney | Neutral → Buy |
| 2019-01-14 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2018-10-31 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2018-10-17 | 개시 | Goldman | Neutral |
| 2018-06-15 | 개시 | Argus | Buy |
| 2017-07-13 | 개시 | Wells Fargo | Market Perform |
| 2017-02-09 | 개시 | Citigroup | Buy |
| 2017-01-18 | 개시 | Deutsche Bank | Buy |
| 2016-11-10 | 재개 | Leerink Partners | Outperform |
| 2015-01-21 | 재확인 | Robert W. Baird | Outperform |
| 2013-09-20 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
모두보기
바이오-테크네 주식(TECH)의 최신 뉴스
Bio-techne’s technology supports FDA approval of rare skin disorder therapy - Investing.com
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
Bio-Techne stock price target lowered to $75 by Scotiabank - Investing.com South Africa
Minnesota's highest-paid CEOs made 7% more, with highest paid making $59.4M - Star Tribune
Assessing Bio-Techne: Insights From 7 Financial Analysts - Benzinga
Bio-Techne (TECH) Receives Buy Rating with $65 Price Target from TD Cowen | TECH Stock News - GuruFocus
Bio-Techne (TECH): TD Cowen Initiates Coverage with Buy Rating | - GuruFocus
5 Revealing Analyst Questions From Bio-Techne’s Q1 Earnings Call - Yahoo Finance
Is There Now An Opportunity In Bio-Techne Corporation (NASDAQ:TECH)? - Yahoo Finance
How To Trade (TECH) - news.stocktradersdaily.com
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock - Yahoo Finance
Bio-Techne stock holds steady as Stifel maintains $60 price target - Investing.com
Is Bio-Techne Stock Underperforming The Nasdaq? - Barchart.com
Major Breakthrough: Bio-Techne and USP Join Forces to Transform Gene Therapy Development Process - Stock Titan
First Week of August 15th Options Trading For Bio-Techne (TECH) - Nasdaq
Bio-Techne (NASDAQ:TECH) stock performance lags Nasdaq Composite in recent years - Kalkine Media
Bio-Techne Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
How the (TECH) price action is used to our Advantage - news.stocktradersdaily.com
Bio-Techne Director Cashes Out in Significant Stock Sale - TipRanks
Bio-Techne at Goldman Sachs Conference: Strategic Growth Amid Challenges - Investing.com
TECH Q1 Earnings Call: Management Highlights Market Uncertainties and Strategic Mitigation Efforts - Yahoo Finance
Transcript : Bio-Techne Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 10 - MarketScreener
Bio-Techne To Present At Goldman Sachs Global Healthcare Conference; Webcast At 10:40 AM ET - Nasdaq
ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics - Yahoo Finance
Bio-Techne (TECH) Maintains 'Buy' Rating with $75 Price Target | TECH Stock News - GuruFocus
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact By Investing.com - Investing.com South Africa
Benchmark maintains Buy rating on Bio-Techne stock amid tariff impact - Investing.com India
Stochastic Optical Reconstruction Miicroscope Market Size, - openPR.com
Deutsche Bank Adjusts Bio-Techne Price Target to $66 From $70 - marketscreener.com
Bio-Techne at Jefferies Conference: Strategic Growth Amid Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - marketscreener.com
Bio-Techne at William Blair Growth Stock: Strategic Insights and Challenges - Investing.com
Transcript : Bio-Techne Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 02 - marketscreener.com
Spotting Winners: Bio-Techne (NASDAQ:TECH) And Research Tools & Consumables Stocks In Q1 - Yahoo Finance
Bio-Techne Corp (TECH) Stock Analysis: Unveiling a 43% Potential Upside Amid Challenging Valuations - DirectorsTalk Interviews
Wells Fargo Begins Coverage of Bio-Techne (TECH) Stock, Gives PT of $59 - Insider Monkey
Wells Fargo starts Bio-Techne with Overweight, $59 target - Investing.com Australia
Bio-Techne stock price target cut to $65 by Argus - Investing.com South Africa
Wells Fargo Initiates Coverage on Bio-Techne (TECH) with Overwei - GuruFocus
Wells Fargo starts Bio-Techne with Overweight, $59 target By Investing.com - Investing.com Canada
Demystifying Bio-Techne: Insights From 7 Analyst Reviews - Benzinga
Argus Adjusts Price Target on Bio-Techne to $65 From $90 - marketscreener.com
Wells Fargo Initiates Bio-Techne at Overweight With $59 Price Target - marketscreener.com
Bio-Techne Corporation (TECH): A Bull Case Theory - Insider Monkey
Bio-Techne Corporation: An Insight Into The Pharmaceutical Market Dynamics & China's Economic & Regulatory Environment! - Smartkarma
Is Bio-Techne Stock The Right Pick For Your Portfolio Now? - Barchart.com
Is Bio-Techne Stock the Right Pick for Your Portfolio Now? - Yahoo Finance
Bio-Techne Sets Triple Conference Appearance: William Blair, Jefferies, and Goldman Sachs in June - Stock Titan
Bio-Techne to Present at Investor Conferences - Yahoo Finance
Bio-Techne Corp. stock underperforms Wednesday when compared to competitors - MSN
Cetera Investment Advisers Sells 887 Shares of Bio-Techne Co. (NASDAQ:TECH) - Defense World
바이오-테크네 (TECH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
바이오-테크네 주식 (TECH) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Herr Amy E. | Director |
Jun 09 '25 |
Sale |
49.77 |
1,280 |
63,705 |
1,976 |
0.19%
0.64%
자본화:
|
볼륨(24시간):